Horizon buying Vidara for Actimmune, Irish HQ

Horizon Pharma believes that it will become even more profitable than expected this year after the company closes its $600m acquisition of Vidara Therapeutics in mid-2014 and adds Vidara's roughly $60m in annual Actimmune (interferon gamma-1b) revenue to its balance sheet.